Market Overview

The Ivosidenib market is predicted to develop at a compound annual growth rate (CAGR) of xx% from 2024 to 2034, when it is projected to reach USD xx Billion, based on an average growth pattern. The market is estimated to reach a value of USD xx Billion in 2024.

SOURCE: We Market Research

AML and cholangiocarcinoma are two tumors that can be treated with ivosidenib, a targeted cancer medication. It selectively blocks IDH1 gene alterations, which can cause these tumors' aberrant cell proliferation. Ivosidenib helps restore normal cell differentiation by targeting the IDH1 mutation, which slows or stops the progression of cancer. It offers a customized treatment plan and is recommended for patients with proven IDH1-mutated tumors. By concentrating on the genetic makeup of a patient's tumor, this medication advances targeted therapy and enables more efficient and customized cancer treatment.

The growing prevalence of diseases like acute myeloid leukemia (AML) and cholangiocarcinoma with IDH1 mutations is driving the global Ivosidenib market. This targeted therapy is becoming more and more in demand as precision medicine and genetic testing advance. Its market presence is increased by regulatory approvals from organizations such as the FDA and EMA, and further research could lead to a wider range of medicinal applications. Good reimbursement practices in strategic areas also improve uptake and accessibility. All of these elements work together to fuel the rising demand for ivosidenib as a customized cancer treatment on a worldwide scale.

Market Scope

Ivosidenib Industry: Dynamics & Restrains

Market opportunity:

We Market Research: Ivosidenib Dashboard

Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.

Ivosidenib Segmentation

Market- By Indication Analysis

By Indication, the Ivosidenib Market is Categories into Acute Myeloid Leukemia (AML), Cholangiocarcinoma, Other Indications. The Acute Myeloid Leukemia (AML) segment accounts for the largest share of around 86% in 2024.

The segment for AML dominates the market due to the significant prevalence of this condition and the urgent need for effective treatments. Ivosidenib is particularly effective for patients with AML who have a specific mutation in the IDH1 gene, making it a targeted therapy. The high incidence of AML and the critical nature of the disease contribute to the dominance of this segment in the market.

The following segments are part of an in-depth analysis of the global Ivosidenib market:

Ivosidenib Industry: Regional Analysis

North America Market Forecast

North America dominates the Ivosidenib Market with the highest revenue generating market with share of more than 48%. Advanced healthcare infrastructure and high healthcare spending fuel market growth. The presence of major pharmaceutical companies and research institutions supports robust R&D, while a favorable regulatory environment, particularly FDA approvals, facilitates the rapid introduction of Ivosidenib for cancer treatment.

Europe Market Statistics

Europe's strong emphasis on oncology R&D and increasing cancer prevalence drive demand. Government initiatives and funding for cancer treatment further boost the market, while EMA approvals ensure standardized access to Ivosidenib across multiple countries, supporting growth despite stringent regulations.

Asia Pacific Market Forecasts

Asia Pacific is expected to be the fastest-growing regional segment of the Ivosidenib market during the forecast period. In the Asia Pacific region, rapidly growing populations, aging demographics, and increasing cancer awareness are key drivers. Expanding healthcare infrastructure, particularly in emerging economies like China and India, along with rising demand for advanced treatments, position Asia-Pacific as a high-growth region for Ivosidenib.

Key Market Players

·         Agios Pharmaceuticals 

1.      Global Ivosidenib Market Introduction and Market Overview

1.1.    Objectives of the Study

1.2.    Global Ivosidenib Market Scope and Market Estimation

1.2.1. Global Ivosidenib Overall Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2034)

1.2.2. Global Ivosidenib Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2034

1.3.    Market Segmentation

1.3.1. Indication of Global Ivosidenib Market

1.3.2. Dosage Form of Global Ivosidenib Market

1.3.3. Distribution Channel of Global Ivosidenib Market

1.3.4. End-User of Global Ivosidenib Market

1.3.5. Region of Global Ivosidenib Market

2.      Executive Summary

2.1.    Market Dynamics

2.1.1. Drivers

2.1.2. Limitations

2.1.3. Opportunities

2.1.4. Impact Analysis of Drivers and Restraints

2.2.    Pricing Trends Analysis & Average Selling Prices (ASPs)

2.3.    Key Mergers & Acquisitions, Expansions, JVs, Funding / VCs, etc.

2.4.    Porter’s Five Forces Analysis

2.4.1. Bargaining Power of Suppliers

2.4.2. Bargaining Power of Buyers

2.4.3. Threat of Substitutes

2.4.4. Threat of New Entrants

2.4.5. Competitive Rivalry

2.5.      Market Investment Opportunity Analysis (Top Investment Pockets), By Segments & By Region

3.      Global Ivosidenib Market Estimates & Historical Trend Analysis (2019 - 2023)

4.      Global Ivosidenib Market Estimates & Forecast Trend Analysis, by Indication

4.1.    Global Ivosidenib Market Revenue (US$ Mn) Estimates and Forecasts, by Indication, 2019 to 2034

4.1.1. Acute Myeloid Leukemia (AML)

4.1.2. Cholangiocarcinoma

4.1.3. Other Indications

5.      Global Ivosidenib Market Estimates & Forecast Trend Analysis, by Dosage Form

5.1.    Global Ivosidenib Market Revenue (US$ Mn) Estimates and Forecasts, by Dosage Form, 2019 to 2034

5.1.1. Tablet

5.1.2. Others

6.      Global Ivosidenib Market Estimates & Forecast Trend Analysis, by Distribution Channel

6.1.    Global Ivosidenib Market Revenue (US$ Mn) Estimates and Forecasts, by Distribution Channel, 2019 to 2034

6.1.1. Hospitals

6.1.2. Specialty Clinics

6.1.3. Online Pharmacies

6.1.4. Retail Pharmacies

7.      Global Ivosidenib Market Estimates & Forecast Trend Analysis, by End-User

7.1.    Global Ivosidenib Market Revenue (US$ Mn) Estimates and Forecasts, by End-User, 2019 to 2034

7.1.1. Hospitals & Clinics

7.1.2. Research Institutes

7.1.3. Others

8.      Global Ivosidenib Market Estimates & Forecast Trend Analysis, by region

8.1.    Global Ivosidenib Market Revenue (US$ Mn) Estimates and Forecasts, by region, 2019 to 2034

8.1.1. North America

8.1.2. Europe

8.1.3. Asia Pacific

8.1.4. Middle East & Africa

8.1.5. South America

9.      North America Ivosidenib Market: Estimates & Forecast Trend Analysis

9.1.    North America Ivosidenib Market Assessments & Key Findings

9.1.1. North America Ivosidenib Market Introduction

9.1.2. North America Ivosidenib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

9.1.2.1.   By Indication

9.1.2.2.   By Dosage Form

9.1.2.3.   By Distribution Channel

9.1.2.4.   By End-User

9.1.2.5.   By Country

9.1.2.5.1.     The U.S.

9.1.2.5.2.     Canada

9.1.2.5.3.     Mexico

10.  Europe Ivosidenib Market: Estimates & Forecast Trend Analysis

10.1.  Europe Ivosidenib Market Assessments & Key Findings

10.1.1.   Europe Ivosidenib Market Introduction

10.1.2.   Europe Ivosidenib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

10.1.2.1.    By Indication

10.1.2.2.    By Dosage Form

10.1.2.3.    By Distribution Channel

10.1.2.4.    By End-User

10.1.2.5.    By Country

10.1.2.5.1. Germany

10.1.2.5.2. U.K.

10.1.2.5.3. France

10.1.2.5.4. Italy

10.1.2.5.5. Spain

10.1.2.5.6. Russia

10.1.2.5.7. Rest of Europe

11.  Asia Pacific Ivosidenib Market: Estimates & Forecast Trend Analysis

11.1.  Asia Pacific Market Assessments & Key Findings

11.1.1.   Asia Pacific Ivosidenib Market Introduction

11.1.2.   Asia Pacific Ivosidenib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

11.1.2.1.    By Indication

11.1.2.2.    By Dosage Form

11.1.2.3.    By Distribution Channel

11.1.2.4.    By End-User

11.1.2.5.    By Country

11.1.2.5.1. China

11.1.2.5.2. Japan

11.1.2.5.3. India

11.1.2.5.4. Australia

11.1.2.5.5. South Korea

11.1.2.5.6. ASEAN

11.1.2.5.7. Rest of Asia Pacific

12.  Middle East & Africa Ivosidenib Market: Estimates & Forecast Trend Analysis

12.1.  Middle East & Africa Market Assessments & Key Findings

12.1.1.   Middle East & Africa Ivosidenib Market Introduction

12.1.2.   Middle East & Africa Ivosidenib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

12.1.2.1.    By Indication

12.1.2.2.    By Dosage Form

12.1.2.3.    By Distribution Channel

12.1.2.4.    By End-User

12.1.2.5.    By Country

12.1.2.5.1. U.A.E.

12.1.2.5.2. Saudi Arabia

12.1.2.5.3. Egypt

12.1.2.5.4. South Africa

12.1.2.5.5. Rest of Middle East & Africa

13.  South America Ivosidenib Market: Estimates & Forecast Trend Analysis

13.1.  South America Market Assessments & Key Findings

13.1.1.   South America Ivosidenib Market Introduction

13.1.2.   South America Ivosidenib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

13.1.2.1.    By Indication

13.1.2.2.    By Dosage Form

13.1.2.3.    By Distribution Channel

13.1.2.4.    By End-User

13.1.2.5.    By Country

13.1.2.5.1. Brazil

13.1.2.5.2. Argentina

13.1.2.5.3. Colombia

13.1.2.5.4. Rest of South America

14.  Competition Landscape

14.1.  Global Ivosidenib Market Competition Matrix & Benchmarking, by Leading Players / Innovators / Emerging Players / New Entrants

14.2.  Global Ivosidenib Market Competition White Space Analysis, By End-user

14.3.  Global Ivosidenib Market Competition Heat Map Analysis, By End-user

14.4.  Global Ivosidenib Market Concentration & Company Market Shares (%) Analysis, 2022

15.  Company Profiles

15.1.                     Agios Pharmaceuticals.

15.1.1.   Company Overview & Key Stats

15.1.2.   Financial Performance & KPIs

15.1.3.   Product Portfolio

15.1.4.   Business Strategy & Recent Developments

* Similar details would be provided for all the players mentioned below 

16.  Research Methodology

16.1.  External Transportations / Databases

16.2.  Internal Proprietary Database

16.3.  Primary Research

16.4.  Secondary Research

16.5.  Assumptions

16.6.  Limitations

16.7.  Report FAQs

17.  Research Findings & Conclusion